Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Macugen pegaptanib regulatory update

FDA's Dermatologic and Ophthalmic Drugs advisory committee gave a favorable panel review for an NDA from the companies for Macugen

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE